CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 112 enrolled
Drug / intervention
CBP-307 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04818229
NCT04818229Phase 1Completed
CompareCT.gov

A Phase I, Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Positive-Controlled Study to Investigate the Effects of CBP-307 on the QTc Interval in Healthy Subjects

Connect Biopharma Australia Pty Ltd·interventional·Posted Mar 26, 2021·Updated Nov 4, 2024

In Brief

A Phase 1 clinical trial evaluating CBP-307, Placebo-matched CBP-307, and 2 other interventions for Autoimmune Diseases. Completed, enrolled 112 participants across 2 sites in 2 countries.

Detailed Summary

This study will investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutoimmune Diseases
CountriesAustralia, United States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedMar 26, 2021
Enrollment StartJun 1, 2021
Primary CompletionMar 20, 2022
Study CompletionMar 30, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.3 years ago

Interventions

CBP-307drug

CBP-307 capsules oral administration.

Placebo-matched CBP-307drug

Placebo-matched CBP-307 capsules oral administration.

Moxifloxacin (Avelox)drug

Moxifloxacin tablets oral administration。

Placebo-matched Moxifloxacindrug

Placebo-matched Moxifloxacin tablets oral administration.